Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) EBIT (2019 - 2026)

Atea Pharmaceuticals' EBIT history spans 8 years, with the latest figure at -$48.0 million for Q1 2026.

  • Quarterly EBIT fell 22.97% to -$48.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$189.9 million through Mar 2026, down 17.06% year-over-year, with the annual reading at -$180.9 million for FY2025, 6.25% up from the prior year.
  • EBIT came in at -$48.0 million for Q1 2026, up from -$54.9 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$16.3 million in Q3 2022 to a low of -$69.8 million in Q1 2024.
  • The 5-year median for EBIT is -$41.3 million (2025), against an average of -$42.2 million.
  • Year-over-year, EBIT tumbled 471.76% in 2022 and then skyrocketed 44.07% in 2025.
  • Atea Pharmaceuticals' EBIT stood at -$39.9 million in 2022, then dropped by 16.73% to -$46.6 million in 2023, then grew by 16.2% to -$39.0 million in 2024, then plummeted by 40.76% to -$54.9 million in 2025, then rose by 12.61% to -$48.0 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's EBIT are -$48.0 million (Q1 2026), -$54.9 million (Q4 2025), and -$45.6 million (Q3 2025).